Neurocrine Biosciences (NASDAQ:NBIX) released its earnings results on Tuesday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.11), Bloomberg Earnings reports. During the same period last year, the firm earned ($0.51) EPS.
Shares of Neurocrine Biosciences (NBIX) opened at $83.69 on Wednesday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. The company has a market cap of $7,271.47, a P/E ratio of -37.70, a P/E/G ratio of 6.41 and a beta of 0.26. Neurocrine Biosciences has a fifty-two week low of $39.21 and a fifty-two week high of $91.82.
In related news, Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $855,000.00. Following the completion of the sale, the director now directly owns 34,250 shares in the company, valued at $3,082,500. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 337,950 shares of company stock valued at $26,613,876. 4.80% of the stock is currently owned by corporate insiders.
NBIX has been the topic of several analyst reports. Robert W. Baird reissued a “buy” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 3rd. Needham & Company LLC lifted their target price on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Piper Jaffray Companies reissued a “buy” rating and issued a $76.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Oppenheimer set a $95.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Monday, January 15th. Finally, Deutsche Bank reissued a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average target price of $85.47.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/neurocrine-biosciences-nbix-posts-quarterly-earnings-results-misses-estimates-by-0-11-eps.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.